Clinical Trials & Research

clinical trialsMany of today's most effective standard treatments are based on the results of previous clinical studies, and many cancer patients are now living longer because of progress made through clinical trials. Clinical trials offer high quality cancer care and also allow patients the opportunity to advance scientific knowledge and help future patients.

Ongoing research is essential in the fight against cancer, and it is one of the major objectives of the Edwards Comprehensive Cancer Center.

Clinical trials currently available

Code Description
B-49 A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer.
E2108 A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast Cancer.
E2108 A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Women with Metastatic Breast Cancer.
N093B Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients with Triple Negative Metastatic Breast Cancer.
NSABP B-43 A Phase III Clinical Trial Comparing Trastuzumab (Herceptin) Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy.
NSABP B-47 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cycloshospamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk node negative HER2-Low Invasive Breast Cancer.
RTOG 1005 A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer.
S1007 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.
  • Page last updated: Nov 29, 2013
  • Share to Facebook Share to Twitter More...
Search in:

Show search options